Tetra Natural Health Inc. (TBPMF) Announces Upcoming Launch of Hemp Energy Drink

Hemp Energy Drink is developed for those who want to have a clear and focused mind and live an active and fun lifestyle. It can be consumed whenever people are in need of energy whilst working, driving or playing sports and leisure activities. The functional benefits of hemp energy drink are mainly to help for concentration, alertness and to contribute to mental performance and reduction of fatigue.

Hemp Energy Drinks are already available in the U.S.A. and in several European countries, and the European Food Safety Authority confirmed the positive health effects related to the ingredients of Hemp Energy Drink.

Tetra Natural Health has a team of natural health experts that have been preparing to commercialize products containing hemp or that act on the cannabinoid receptors under the existing Food and Drug regulations. To lead and support the team, Tetra recently announced the arrival of Richard Giguere, Executive Vice President Commercial Operations who will implement and oversee the natural health product commercial sales and growth strategy.

Richard has more than 20 years’ experience in sales and marketing including OTC, natural products and original pharmaceutical medications. His arrival was perfectly aligned with Tetra Natural Health’s goal to develop and sell hemp, cannabis and cannabinoid-based OTC (self-care) products to leverage the post-legalization market.  Tetra obtained the rights to the TMA and plans on expanding this food product line as part of a structured sales driven growth plan.

About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc, (TBP.V) (TBPMF) that is focusing on retail commercialization of hemp, cannabis or cannabinoid-based products authorized by Health Canada for sale.

Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.